Iparomlimab and Tuvonralimab (QL1706)

DRUG12 trials

Conditions

Advanced Gastric CancerBiliary Tract Cancer (BTC)Breast CancerEndometrial CancerGastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction AdenocarcinomaGastroesophageal Junction Cancer

Phase 2

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

RecruitingNCT06932068

Qilu Hospital of Shandong UniversityHER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Start: 2025-03-26End: 2027-10-31Target: 77Updated: 2026-05-07

Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Not yet recruitingNCT06954116

Tongji HospitalResectable Hepatocellular Carcinoma With High Risk of Recurrence

Start: 2025-08-01End: 2029-04-01Target: 26Updated: 2025-06-13

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Not yet recruitingNCT07117877

Fudan UniversityOvarian Cancer (OvCa), Platinum Refractory Epithelial Ovarian Cancer, Platinum Resistant Ovarian Cancer

Start: 2025-09-15End: 2027-08-31Target: 33Updated: 2025-08-28

Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

RecruitingNCT07315854

Beijing Friendship HospitalAdvanced Gastric Cancer, Gastric Cancer (GC), Gastroesophageal Junction Cancer +1

Start: 2025-11-04End: 2029-12-31Target: 32Updated: 2026-01-06

Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer

Not yet recruitingNCT07369986

Women's Hospital School Of Medicine Zhejiang UniversityEndometrial Cancer, Immunotherapy, Mismatch Repair Deficiency

Start: 2026-03-01End: 2028-12-31Target: 30Updated: 2026-01-27

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

Not yet recruitingNCT07502014

Huazhong University of Science and TechnologymCRC, Metastatic Colorectal Cancer (CRC)

Start: 2026-05-01End: 2029-12-31Target: 60Updated: 2026-03-30

Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer

RecruitingNCT07646301

Sun Yat-sen UniversityLocally Advanced, Uterine Cervical Neoplasms

Start: 2026-07-01End: 2029-07-01Target: 103Updated: 2026-06-12

QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer

RecruitingNCT07733115

Shanghai Zhongshan HospitalBiliary Tract Cancer (BTC)

Start: 2026-07-20End: 2029-12-31Target: 38Updated: 2026-07-29

Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Not yet recruitingNCT07776080

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyHCC - Hepatocellular Carcinoma

Start: 2026-10-01End: 2028-10-01Target: 35Updated: 2026-08-20

QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy

Not yet recruitingNCT07782840

Hebei Medical University Fourth HospitalBreast Cancer

Start: 2026-10-01End: 2028-12-01Target: 40Updated: 2026-08-26

Phase 3

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Not yet recruitingNCT06789796

Qilu Pharmaceutical Co., Ltd.Small-cell Lung Cancer

Start: 2025-02-28End: 2030-03-31Target: 636Updated: 2025-02-11

Phase 4

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruitingNCT07502027

Huazhong University of Science and TechnologyGastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma

Start: 2026-06-01End: 2029-06-30Target: 55Updated: 2026-03-30

Related Papers

A double-blind, double-dummy, randomized, controlled phase 3 trial of iparomlimab and tuvonralimab (QL1706) vs QL1604 as consolidation therapy following concurrent or sequential chemoradiotherapy (cCRT/sCRT) in patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).